Breast cancer patients place huge emphasis on gene expression profiling test

April 28, 2014, St. Michael's Hospital

Gene expression profiling tests play a critical role when women with early-stage breast cancer decide whether to have chemotherapy, but many of them do not fully understand what some of the test results mean, new research suggests.

Current guidelines for treating early-stage —cancer that has not spread to nearby lymph nodes or other parts of the body—result in thousands of women receiving without benefitting from it.

A profiling test can help differentiate women who might benefit from chemotherapy versus those that might not. The test analyzes the patterns of 21 different genes within the cancer cells to help predict how likely it is that a women's cancer will recur within 10 years after initial treatment and how beneficial chemotherapy will be to her.

Dr. Yvonne Bombard, a genomics and health services researcher in the Li Ka Shing Knowledge Institute of St. Michael's Hospital, said women she interviewed understood the test would indicate whether chemotherapy would be beneficial to them.

But, she said, many thought the test reflected their unique circumstances and did not understand that their test result was based on larger population statistics.

Her findings have been published online in the journal Current Oncology.

"Patients often viewed their GEP results as providing information that was more scientifically valid, uniquely personalized and emotionally significant than any other information they had received," Dr. Bombard said. "For many, the test was a transformational element that empowered them, allowed them to feel confident in their decisions and may even have rescued them from unnecessary chemotherapy."

The GEP test was a main determinant of patients' chemotherapy decisions, despite their misunderstanding of the test and its validity.

"GEP is one of many factors that in consultation with their oncologists, should consider when choosing treatment for early stage breast cancer," said Dr. Maureen Trudeau, a medical oncologist of the Breast Care team and head of the Medical Oncology Program at Sunnybrook's Odette Cancer Centre, and study co-author. "The GEP does not replace standard prognostic information but adds one more piece of information."

Clinical guidelines suggest the majority of the 22,600 Canadians whose breast cancer tests negative for human epidermal growth factor receptor 2 (HER2) should be offered chemotherapy. Yet only 15 per cent of such cancers will recur, suggesting that about 8,500 Canadian patients are treated without benefit each year.

Explore further: Receiving chemotherapy after a breast cancer diagnosis may affect a patient's employment

Related Stories

Receiving chemotherapy after a breast cancer diagnosis may affect a patient's employment

April 28, 2014
A new study has found that loss of paid employment after a diagnosis of early-stage breast cancer may be common and potentially related to the type of treatment patients received. Published early online in Cancer, a peer-reviewed ...

Gene expression profile testing increasing in breast cancer

May 18, 2012
(HealthDay) -- From 2006 to 2008, the use of gene expression profile (GEP) testing increased, correlating with a decrease in the percentage of women with hormone receptor (HR)-positive breast cancer receiving adjuvant chemotherapy, ...

Additional drug shows promise for women with triple-negative breast cancer

December 13, 2013
In a nationwide study of women with "triple-negative" breast cancer, adding the chemotherapy drug carboplatin or the angiogenesis inhibitor Avastin to standard chemotherapy drugs brought a sharp increase in the number of ...

New breast cancer test will help more women avoid unnecessary chemotherapy

July 3, 2013
A new genetic test for one of the most common forms of breast cancer will help doctors better identify those women who should be considered for chemotherapy, and those who can avoid it, say researchers.

Molecular subtyping of breast cancer can better identify women at high risk of recurrence

March 6, 2014
A method called molecular subtyping can help doctors better determine which of their breast cancer patients are at high risk of getting breast cancer again, a new study led by the University of South Florida reports. This ...

Combined therapy linked to lower chance of recurrence in women with small, HER2+ breast cancers

December 11, 2013
In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery or radiation therapy were very unlikely to have ...

Recommended for you

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.